TY  - JOUR
T1  - Diagnostic value of liquid biopsy in the era of precision medicine : 10 years of clinical evidence in cancer
AU  - Caputo, Vincenza
AU  - Ciardiello, Fortunato
AU  - Della Corte, Carminia Maria
AU  - Martini, Giulia
AU  - Troiani, Teresa
AU  - Napolitano, Stefania
Y1  - 2023///
JO  - Exploration of Targeted Anti-tumor Therapy
VL  - 4
IS  - 1
SP  - 102
EP  - 138
DO  - 10.37349/etat.2023.00125
UR  - https://www.explorationpub.com/Journals/etat/Article/1002125
AB  - Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring oncological decision-making. It analyzes different blood-circulating biomarkers and circulating tumor DNA (ctDNA) is the preferred one. Nevertheless, tissue biopsy remains the gold standard for molecular evaluation of solid tumors whereas liquid biopsy is a complementary tool in many different clinical settings, such as treatment selection, monitoring treatment response, cancer clonal evolution, prognostic evaluation, as well as the detection of early disease and minimal residual disease (MRD). A wide number of technologies have been developed with the aim of increasing their sensitivity and specificity with acceptable costs. Moreover, several preclinical and clinical studies have been conducted to better understand liquid biopsy clinical utility. Anyway, several issues are still a limitation of its use such as false positive and negative results, results interpretation, and standardization of the panel tests. Although there has been rapid development of the research in these fields and recent advances in the clinical setting, many clinical trials and studies are still needed to make liquid biopsy an instrument of clinical routine. This review provides an overview of the current and future clinical applications and opening questions of liquid biopsy in different oncological settings, with particular attention to ctDNA liquid biopsy.
ER  -